13 Aug 2020


  • BMS heeds BIO’s call to ‘walk the talk’ – BioCentury
  • Covid-19: Covid-19 vaccine hopeful doubles on China stock market debut – Financial Times
  • Covid-19: Pfizer, BioNTech publish data on ongoing Covid vaccine phase 1/2 – Bloomberg
  • Breast cancer tests in 40s a lifesaver ‘for thousands’ – The Times
  • Omnicell to buy PSG’s 340B Link business for $225m cash – Bloomberg
  • Gyroscope Therapeutics announces initiation of phase 2 programme evaluating its investigational gene therapy, GT005, for dry age-related macular degeneration
  • FDA gives thumbs up to Synergy for HBR indication – BioWorld
  • Roche offloads clinical-phase cancer drug to Celleron – FierceBiotech
  • Covid-19: Mexico and Argentina agree to produce AstraZeneca Oxford vaccine – Bloomberg
  • Baxter’s HF20, ST sets gain FDA emergency use in CRRT during pandemic – FirstWord MedTech

Jeff Cranmer of BioCentury reports that a week after BIO unveiled its BIOEquality initiative, Bristol Myers Squibb (BMS) said it is preparing to invest $300m to increase diversity in clinical trials of its therapies and the representation of Blacks and Latinos at all levels of the company. BMS pledged to achieve gender parity among its executives worldwide by 2022. In the same time frame, the company committed to doubling executive representation of Black and Latino employees in the US. 
BioCentury >>
Christian Shepherd and Hudson Lockett of the Financial Times report that shares in a pharmaceutical group that is developing a coronavirus vaccine alongside China’s military more than doubled on its trading debut. CanSino Biologics’ stock surged as much as 127% on its first day of trading on Shanghai’s Nasdaq-like Star Market after the company raised $748.9m in a secondary share offering. 
Financial Times >>
Polina Noskova of Bloomberg reports that Pfizer and BioNTech have reported preliminary data
from their BNT162 mRNA-based Covid-19 vaccine candidate study. Data show that BNT162b1 was administered to candidates in a dose that was well tolerated and granted dose dependent immunogenicity.
Bloomberg >>
Katie Gibbons of The Times reports that screening women in their forties for breast cancer could save thousands of lives, according to a British study of more than 160,000 cases. The present screening programme is offered only to women aged 50 to 70 every three years but research shows that up to 400 lives a year could be saved if it was extended to younger women.
The Times >>
Luzi Javier of Bloomberg reports that Omnicell said it agreed to acquire Pharmaceutical Strategies Group’s 340B Link business for $225m in cash, subject to customary adjustments. The acquisition expands Omnicell’ pharmacy supply chain capabilities for efficient, compliant management of 340B programs. 
Bloomberg >>
Gyroscope Therapeutics announced the initiation of its phase 2 programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Nadia Waheed, M.D., MPH, CMO of Gyroscope said: “We are excited about the potential of GT005 for people with dry AMD. Research suggests GT005 may be best suited for people with certain mutations in their Complement Factor I gene. However, evidence also suggests it may have potential for a broader population of people with GA.” 
Gyroscope Therapeutics >>
Liz Hollis of BioWorld reports that Boston Scientific has received the US Food and Drug Administration’s nod for a high bleeding risk (HBR) indication for the Synergy drug-eluting stent system. The company said the approval makes Synergy the first such platform in the US with an indication for HBR.
BioWorld >>
Nick Taylor of FierceBiotech reports that Roche has offloaded its anti-CSF1R monoclonal antibody emactuzumab to Celleron Therapeutics. The licensing deal comes almost two years after Roche dropped the tumour microenvironment modulator after putting it through a clutch of early-phase studies in solid tumor patients.
FierceBiotech >>
Eric Martin of Bloomberg reports that Mexico and Argentina have reached agreements to produce AstraZeneca’s promising Covid-19 vaccine for Latin America. The countries will make 150m to 250m initial doses of the potential Covid-19 vaccine designed by scientists at the University of Oxford after the required trials.
Bloomberg >>
Katie Bell of FirstWord MedTech reports that Baxter has received US Food and Drug Administration emergency-use authorisations for the company’s HF20 set and ST set used in continuous renal replacement therapy (CRRT) during the Covid-19 pandemic. Reaz Rasul, general manager of Baxter’s acute therapies business, remarked that, “with the continued need for CRRT products, the addition of the HF20 set and ST set offers healthcare providers and hospitals greater flexibility to meet the varying needs of patients, while making more CRRT sets available in the US.”
FirstWord MedTech >>

We Are Here To Help

In this uncertain time, FTI Consulting stands ready to support all your communications needs.   We are currently engaged across the business with hundreds of companies addressing the intense challenge of the coronavirus and are deploying decades of issues management experience to advising clients on communicating with all stakeholders.   We are fully deploying our broad range of capabilities to help our clients manage the internal and cultural change aspects, public affairs implications, social and digital channels as well as broader global needs. As a multi-practice business advisory firm, we can also help you work through important operational concerns and challenges currently facing your business.   We recognise that this unprecedented situation is challenging and are available to help.

Please contact the FTI Lifesciences and Healthcare team if you think we can help >>

Upcoming events

  • Canaccord Genuity Annual Growth Conference, Virtual (12-13 August)
  • Citi’s Annual BioPharma Conference, Virtual (9-10 September)
  • Baird Healthcare Conference, Virtual (9-10 September)
  • Wells Fargo Healthcare Conference, Virtual (9-10 September)

Register to receive up-to-date information and advice on tax developments within your industry.